The lawsuit alleges that Unicycive misled shareholders by failing to disclose critical manufacturing issues. Specifically, the complaint claims the company did not inspect its third-party vendor’s facility or audit its compliance with FDA standards. Consequently, the company lacked a reasonable basis to suggest the vendor had resolved previously cited deficiencies, creating an undisclosed risk of regulatory delays for the drug oxylanthanum carbonate (OLC).

Investors who incurred losses during the class period are eligible to participate in the litigation under a contingency fee arrangement, meaning no out-of-pocket costs are required. Those interested in serving as a lead plaintiff must file a motion with the court by the November deadline. While the Rosen Law Firm is actively recruiting participants, no class has been certified yet. Investors retain the right to select their own counsel, remain an absent class member, or choose not to participate at this time.